Материал: Дерматовенерология (2015)

Хирургическое

лечение/СО2-

лазерная абляция***

Келоидный рубец

ДА

Индивидуальное

ДА

лечение каждого

Узкое основание

ДА

очага по схеме

Крупный

малого келоида

(более 5 см2)

НЕТ

НЕТ

Диссеминированные

Частичное лечение

мелкие

зон с повышенной

Бетаметазона

активностью

НЕТ

по аналогии

дипропионат (2 мг) +

с малыми

бетаметазона

ДА

келоидами/отказ

динатрия фосфат (5 мг)/

Обширные

от лечения,

ТАА или криотерапия

сливающиеся

если это приемлемо

для пациента

НЕТ

Комбинация

Полная

ДА

кортикостероидов

с криотерапией/

Клинический

устойчивость

хирургическое

эффект

к терапии

лечение/

лучевая терапия

НЕТ

рубцы

Сохраняющаяся

ДА

Пульсирующий лазер

НЕТ

ДА

НЕТ

гипертрофическиеи

эритема

на красителях

ОКОНЧАНИЕ ТЕРАПИИ

* Коррекция терапии.

Келоидные

** Часто сочетанное поражение (келоидные и гипертрофические рубцы).

*** Необходима последующая профилактическая терапия.

ЛИТЕРАТУРА

1.

Gauglitz G. G., Korting H. C., Pavicic T., Rucicka T., Jeschke M. G. Hyper-

trophic scarring and keloids: pathomechanisms and current and emerging

treatment strategies. Mol Med 2011; 17 (1—2): 113—25.

2.

Love P. B., Kundu R. V. Keloids: an update on medical and surgical treat-

ments. J Drugs Dermatol 2013; 12 (4): 403—9.

3.

Marneros A. G., Krieg T. Keloids: clinical diagnosis, pathogenesis and treat-

ment options. J Detsch Dermatol Ges 2004; 2 (11): 905—13.

4.

Hahn J. M., Glaser K., McFraland K. L., Aronow B. J., Boyce S. T.,

Supp D. M. Keloid-derived keratinocytes exhibit an abnormal gene expression

profile consistent with a distinct causal role in keloid pathology. Wound Repair

Regen 2013; 21 (4): 530—44.

5.

Faler B. J., Macsata R. A., Plummer D., Mishra L., Sidawy A. N. Transfor­

ming growth factor-beta and wound healing. Perspect Vasc Surg Endovasc

Ther 2006; 18: 55—62.

6.

Bettinger D. A., Yager D. R., Diegelmann R. F., Cohen I. K. The effect of

TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plast Re-

constr Surg 1996; 98: 827—33.

7.

Fujiwara M., Muragaki Y., Ooshima A. Upregulation of transforming growth

factor-beta 1 and vascular endothelial growth factor in cultured keloid fibro-

blasts: relevance to angiogenic activity. Arch Dermatol Res 2005; 297: 161—9.

8.

Desmouliere A., Geinoz A., Gabbiani F., Gabbiani G. Transforming growth

factor-beta 1 induces alpha-smooth muscle actin expression in granulation tis-

sue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell

Biol 1993; 122: 103—11.

9.

van der Veen W. M., Bloemen M. C., Ulrich M. M., Molema G., van Zuij­

len P. P., Middelkoop E. et al. Potential cellular and molecular causes of hy-

pertrophic scar formation. Burns 2009; 35 (1): 15—29.

10.

Armour A., Scott P. G., Tredget E. E. Cellular and molecular pathology of

HTS: basis for treatment. Wound Repair Regen 2007; 15 (Suppl. 1): S6—17.

11.

Mustoe T. A., Cooter R. D., Gold M. H., Hobbs F. D. et al. International clin-

ical recommendations on scar management. Plast Reconstr Surg 2002; 110:

560—71.

12.

Fearmonti R., Bond J., Erdmann D., Levinson H. A review of scar scales and

кожи

scar measuring devices. Eplasty 2010; 10: e43.

13.

Perry D. M., McGrouther D.A., Bayat A. Current tools for noninvasive objec-

tive assessment of skin scars. Plast Reconstr Surg 2010; 126: 912—23.

Болезни

14.

Sebastian G., Hackert I., Stein A., Aschoff R. Möglichkeiten zur Objekti­

Fortschritte der operativen und onkologischen Dermatologie. Berlin, Wien:

Blackwell, 2000: 192—7.

15.

Arno A. I. et al. Up-to-date approach to manage keloids and hypertrophic

scars: A useful guide. Burns, 2014.

16.

Gauglitz G. G. Management of keloids and hypertrophic scars: current and

emerging options. Clin Cosmet Investig Dermatol 2013; 6: 103—14.

17.

Balci D. D., Inandi T., Dogramaci C .A., Celik E. DLQI scores in patients

with keloids and hypertrophic scars: a prospective case control study. J Dtsch

Dermatol Ges 2009; 7: 688—92.

18.

Bock O., Schmid-Ott G., Malewski P., Mrowietz U. Quality of life of patients

with keloid and hypertrophic scarring. Arch Dermatol Res 2006; 297: 433—8.

19.

Published by. In: Middelkoop E., Monstrey S., Teot L., Vranckx J. J., editors.

Scar Management Practical Guidelines. Maca-Cloetens; 2011. p. 1—109.

20.

Haedersdal M., Bech-Thomsen N., Poulsen T., Wulf H. C. Ultraviolet expo-

sure influences laser-induced wounds, scars, and hyperpigmentation: a mu-

rine study. Plast Reconstr Surg 1998; 101: 1315—22.

21.

Due E., Rossen K., Sorensen L. T., Kliem A., Karlsmark T., Haedersdal M.

Effect of UV irradiation on cutaneous cicatrices: a randomized, controlled

trial with clinical, skin reflectance, histological, immunohistochemical and

biochemical evaluations. Acta Derm Venereol 2007; 87: 27—32.

22.

Muneuchi G., Suzuki S., Onodera M., Ito O., Hata Y., Igawa H. H. Long-

term outcome of intralesional injection of triamcinolone acetonide for the

treatment of keloid scars in Asian patients. Scand J. Plast Reconstr Surg Hand

Surg 2006; 40: 111—6 (LEVEL B).

23.

Ardehali B., Nouraei S. A., van Dam H., Dex E., Wood S., Nduka C. Ob-

jective assessment of keloid scars with three-dimensional imaging: Quantify-

ing response to intralesional steroid therapy. Plast Reconstr Surg 2007; 119:

556—61 (LEVEL A).

24.

Chowdri N. A., Masarat M., Mattoo A., Darzi M. A. Keloids and hypertro-

рубцы

phic scars: Results with intraoperative and serial postoperative сorticosteroid

injection therapy. Aust N. Z. J. Surg 1999; 69: 655—9 (LEVEL B).

гипертрофические

25.

phic scars and keloids. Hautarzt 1995; 46: 462—6 (LEVEL B).

Zouboulis C. C., Blume U., Büttner P., Orfanos C. E. Outcomes of cryosur-

gery in keloids and hypertrophic scars. A prospective consecutive trial of case

series. Arch Dermatol 1993; 129: 1146—51 (LEVEL B).

26.

Ernst K., Hundeiker M. Results of cryosurgery in 394 patients with hypertro-

27.

Rusciani L., Rossi G., Bono R. Use of cryotherapy in the treatment of keloids.

и

and keloids. Hautarzt 1990; 41: 683—8 (LEVEL B).

Келоидные

J Dermatol Surg Oncol 1993; 19: 529—34 (LEVEL B).

28.

Zouboulis C. C., Orfanos C. E. Cryosurgical treatment of hypertrophic scars

29.

Sharma S., Bhanot A., Kaur A., Dewan S. P. Role of liquid nitrogen alone

compared with combination of liquid nitrogen and intralesional triamcinolone

acetonide in treatment of small keloids. J Cosmet Dermatol 2007; 6: 258—61

(LEVEL B).

30.

Har-Shai Y., Dujovny E., Rohde E., Zouboulis C. C. Effect of skin surface

temperature on skin pigmentation during contact and intralesional cryosur-

gery of keloids. J Eur Acad Dermatol Venereol 2007; 21: 191—8 (LEVEL B).

31.

Norris J. E. The effect of carbon dioxide laser surgery on the recurrence of

keloids. Plast Reconstr Surg 1991; 87: 44—9 (LEVEL B).

32.

Apfelberg D. B., Maser M. R., White D. N., Lash H. Failure of carbon dioxide

laser excision of keloids. Lasers Surg Med 1989; 9: 382—8 (LEVEL B).

33.

Kuo Y. R., Wu W. S., Jeng S. F., Wang F. S., Huang H. C., Lin C. Z. et al. Sup-

pressed TGF-beta1 expression is correlated with upregulation of matrix me-

talloproteinase-13 in keloid regression after flashlamp pulsed-dye laser treat-

ment. Lasers Surg Med 2005; 36: 38—42 (LEVEL C).

34.

Kuo Y. R., Wu W. S., Jeng S. F., Nicolini J., Zubillaga M. Activation of ERK

and p38 kinase mediated keloid fibroblast apoptosis after flashlamp pulsed-dye

laser treatment. Lasers Surg Med 2005; 36: 31—7 (LEVEL C).

35.

Kuo Y. R., Jeng S. F., Wang F. S., Chen T. H., Huang H. C., Chang P. R. et al.

Flashlamp pulsed dye laser (PDL) suppression of keloid proliferation through

down-regulation of TGF-beta1 expression and extracellular matrix expres-

sion. Lasers Surg Med 2004; 34: 104—8 (LEVEL C).

36.

Gold, Michael H. et al. Updated international clinical recommendations on

scar management: part 2—algorithms for scar prevention and treatment. Der-

matologic Surgery 40.8 2014: 825—831.

37.

Kim D. Y., Kim E. S., Eo S. R., Kim K. S., Lee S. Y., Cho B. H. A surgical

approach for earlobe keloid: Keloid fillet flap. Arch Facial Plast Surg 2005;

7: 172—5 (LEVEL B).

38.

Lee Y., Minn K. W., Baek R. M., Hong J. J. A new surgical treatment of keloid:

Keloid core excision. Ann Plast Surg 2001; 46: 135—40 (LEVEL C).

39.

Field L. M. Subtotal keloid excision—a preferable preventative regarding re-

currence. Dermatol Surg 2001; 27: 323—4 (LEVEL C).

40.

Ragoowansi R., Cornes P. G., Moss A. L., Glees J. P. Treatment of keloids by

surgical excision and immediate postoperative single-fraction radiotherapy.

Plast Reconstr Surg 2003; 111: 1853—9 (LEVEL B).

кожи

41.

Subedi N., Roberts F. Radiotherapy treatment of keloid scars and other benign

conditions: Is there a need for a database of patients treated? Br J Dermatol

2009; 161: 194—5 (LEVEL B).

Болезни

42.

Ogawa R., Miyashita T., Hyakusoku H., Akaishi S., Kuribayashi S., Tateno A.